{"id":14686,"date":"2021-06-09T09:25:40","date_gmt":"2021-06-09T09:25:40","guid":{"rendered":"https:\/\/clinlabint.com\/?p=14686"},"modified":"2021-06-09T09:29:20","modified_gmt":"2021-06-09T09:29:20","slug":"why-we-should-be-measuring-ionized-magnesium","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/why-we-should-be-measuring-ionized-magnesium\/","title":{"rendered":"Why we should be measuring ionized magnesium"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Why we should be measuring ionized magnesium<\/h1>\/ in Featured Articles<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

The majority of magnesium in the body is located in bone and muscle; however, the small extracellular proportion of ionized magnesium plays an important role in a number of physiologic processes. Generally, when assessing magnesium concentration, total magnesium is measured. This article discusses the importance of ionized magnesium and why we should be directly measuring this fraction, rather than total magnesium.<\/strong><\/p>\n

<\/p>\n

by Dr Dennis Begos<\/em><\/p>\n

Magnesium<\/h3>\n

Magnesium (Mg) is the fourth most abundant cation in the human body. The majority of it is found intracellularly, more than half in bone, about a third in muscle, and the remainder in soft tissue and extracellular fluid (Fig. 1). Mg is found in the diet from a variety of sources: green leafy vegetables (Mg is a part of the chlorophyll molecule), nuts and seeds, fruits, yogurt and unrefined grains such as wheat and oatmeal. It is absorbed in the gut and excreted by the kidneys. Even though it is found in a wide variety of foods, much of it is lost during processing, and the Mg content of fruits and vegetables has decreased by 20\u201330% over the past 60|years. Thus, it is estimated that up to 60% of healthy adults do not get the recommended amount of Mg in their diet [2]. Although only about 1% of total Mg is located extracellularly, this is an extremely important fraction, as Mg is involved in a multitude of physiologic processes (Table 1), many of which are critical to overall health, including cardiac conduction and contractility, energy production, ion transport and coagulation.<\/p>\n

Ionized magnesium does not always correlate with total magnesium<\/h3>\n

The portion of extracellular Mg that is physiologically active in these processes is ionized Mg (iMg). Mg in serum is found in three states: protein bound (20\u201330%), complexed with anions (5\u201315%), and ionized (55\u201370%) (Fig. 2). Because the amount of bound or complexed Mg can vary significantly, especially in illness, the levels of iMg can vary in an unpredictable way. Conventional laboratory testing typically only measures total serum Mg (tMg), which is often not reflective of iMg. Unlike ionized calcium, which is commonly measured, and which is also readily calculated from the total calcium and albumin levels, iMg is neither commonly measured nor easily calculated [3]. In particular, patients in the ICU, perioperative patients, patients at the extremes of age (elderly or neonatal), and those with chronic kidney disease can have significant variation in their iMg levels without much change in tMg, or vice versa. This variability can be due to changes in serum protein levels, or the variability of anions in the blood which would cause the iMg level to fluctuate. In a study from Sweden, 25% of patients in the ICU had low iMg despite a normal tMg, and 9% had a high iMg in the presence of a normal tMg (See Figure 1 in Johansson & Whiss, 2007 [4]).<\/p>\n

In another study looking at ICU patients, 30% of tMg measurements did not correlate with iMg; the majority of low tMg were false negatives, potentially leading to over-supplementation with Mg and running up laboratory costs (See Figure 1 in Yeh et al., 2017 [5]). Other studies have shown similar findings of a 30% discrepancy between tMg and iMg [6]. The authors of this study commented, \u201cReliable concentrations of serum ionized magnesium can be obtained only by direct measurement and not by calculation from serum total magnesium and albumin\u201d[6]. Thus, it is safe to say that tMg is not reflective of iMg in approximately one-third of patients, and for accurate assessment of functional Mg the iMg is the preferred analyte to measure, especially in critically ill patients. There seems to be no easy way to calculate iMg from tMg. The data presented above deals with hospitalized patients, but a recent study evaluated healthy individuals following an oral Mg supplement. That study found that iMg was a more sensitive marker for evaluating the acute rise of Mg after oral intake, and the study is expanding to a larger randomized, controlled trial [7]. In this group, iMg but not tMg rose following oral ingestion of Mg: \u201cWe demonstrated the superiority of concentrations of iMg2+ in blood, compared to concentrations of total magnesium in serum and total urine magnesium content, as a rapid and sensitive measure of dietary intake of magnesium in healthy humans. The finding that a single dose of 300|mg of magnesium can alter iMg2+, but not total magnesium, suggests that the iMg2+ method is more sensitive\u201d[7].<\/p>\n

Consequences of dysmagnesemia<\/h3>\n

Hypomagnesemia (usually due to inadequate dietary intake) is more prevalent than hypermagnesemia because the kidneys are very good at excreting Mg until creatinine clearance drops below 10|mL\/min [8]. The consequences of disordered magnesium, either hypo or hyper, can be significant. As Mg is involved in numerous physiologic processes, concentrations of it that are outside the norm can affect many systems. One of the most serious and potentially life-threatening complications of hypomagnesemia is cardiac arrhythmias, due to abnormal conduction and contractility of the heart. In the acute setting, hypomagnesemia can also result in seizures, muscle cramps, migraine headaches and secondary abnormalities of other electrolytes such as potassium, sodium and calcium [2]. Hypermagnesemia is seen in people with severe chronic kidney disease, can be seen in people taking medications with magnesium (typically laxatives), and can cause flushing, bradycardia, hypotension, respiratory depression and muscle weakness [2]. Magnesium infusions are also used for treating pregnant women in pre-term labour, where tMg levels are typically closely monitored [9]. Low iMg but not tMg has also been shown to be a risk factor for pre-eclampsia, which again suggests that iMg is the preferred analyte to measure [10].<\/p>\n

There is a significant amount of data to support the fact that either hyper or hypomagnesemia can affect patient outcomes. Most studies evaluating outcomes related to Mg have studied tMg, not iMg. One study that did evaluate iMg in ICU patients found that development of ionized hypomagnesemia was an independent predictor of mortality [11]. Additionally, the study found a poor correlation between tMg and iMg, with up to 85% of patients with low tMg having normal iMg [11]. In a large study from the Mayo Clinic, over 280\u00a6000 patients were retrospectively evaluated, and it was found that patients with a tMg of <1.7 or >2.3|mg\/dL had a higher all-cause mortality than those with a normal tMg on admission. Patients with normal tMg had fewer cardiac arrhythmias and fewer days on the ventilator [12]. In an analysis of over 3500 patients enrolled in the Dallas Heart Study, hypomagnesemia (tMg) was found to be an independent predictor of mortality: for every 0.2|mg\/dL drop in tMg, there was a 20\u201340% increase in all-cause mortality in patients with and without chronic kidney disease (CKD) (See Figure 1 in Ferr\u00e8 et al., 2018; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/ PMC6454476\/figure\/gfx275-F1\/ [13]).<\/p>\n

A large meta-analysis also found an inverse correlation between tMg levels and cardiovascular disease, with a 30% decrease in risk for every 0.2|mmol\/L rise in tMg [14]. The Atherosclerosis Risk in Communities study, a large population-based study, found a link between low tMg and CKD, with lower tMg levels predicting a higher risk of CKD and end-stage renal disease (See Figures 1 & 2 in Tin et al., 2015; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/ PMC4382401\/figure\/F1\/ [15]).<\/p>\n

The exact mechanisms by which hypomagnesemia causes increased morbidity and mortality remain to be fully elucidated, but many sound theories have been proposed. Given the nature of the role of Mg in multiple physiologic processes, there are likely to be several pathways, and they can be broken down into acute and chronic effects. In terms of the acute effects, cardiac arrhythmias due to an altered electrochemical environment are likely to play a big role in sudden death [16]. An additional acute negative event relates to hypomagnesemia in patients with acute infections or sepsis. It has been observed that ICU patients with sepsis and low iMg or tMg have a higher mortality [11, 17]. This could be due to a more aggressive cytokine storm, as Mg is known to play a role in attenuating cytokine production, particularly interleukin (IL)-1, IL-6, and tumour necrosis factor (TNF) [2, 11, 13, 18, 19]. The common thread of the chronic effects is the role of hypomagnesemia in promoting atherosclerotic changes, which can affect numerous organ systems. Low Mg can accelerate the development of atherosclerosis by several avenues:<\/p>\n

\u2022 Endothelial cell dysfunction. It is known that low Mg has an inhibitory effect on endothelial cell proliferation, which can lead to thrombotic or inflammatory changes in arteries [20].<\/p>\n

\u2022 Vascular smooth muscle calcification. Mg deficiency promotes formation of hydroxyapatite crystals, which can lead to calcification of smooth muscle in arteries, a hallmark of atherosclerosis [21, 22]. It may also mediate calcification by its effect on membrane transport of calcium [23].<\/p>\n

\u2022 Hypercoagulability. Magnesium is known to inhibit platelet aggregation, thus low Mg may lead to a thrombotic state [24].<\/p>\n

\u2022 Increased inflammation. It is well-known that inflammation plays a role in the development and progression of atherosclerotic plaques [25].<\/p>\n

These findings are reinforced by a study done in hemodialysis patients in Japan [26]. In over 140\u00a6000 dialysis patients, both high and low Mg were predictors of mortality (See Figure 3 in Sakaguchi et al., 2014; https:\/\/www.kidney-international.org\/article\/ S0085-2538(15)56154-1\/fulltext [26]). Although elevated Mg was not an independent predictor, low Mg was a significant and concentration-dependent predictor of mortality from cardiovascular disease and mortality due to infection [26]. \u201cThe major finding of our study is that a lower serum Mg level was a significant and independent predictor of CVD mortality among chronic hemodialysis patients. We also found a significant association between hypomagnesemia and non-CVD mortality, especially deaths from infection\u201d[26].<\/p>\n

Although these data all show correlation, they do not necessarily prove causation. It is possible that low Mg is an epiphenomenon, or a consequence of the illness, but based on what we know about the physiology of Mg it seems likely that it is at least partially responsible. Several studies suggest this to be the case. In the Framingham Heart Study cohort, patients with a higher dietary intake of Mg had significantly lower rates of coronary artery calcification and aortic calcification [27]. In dialysis patients, using a high-Mg dialysate keeps iMg levels in the normal to slightly elevated range [28, 29]. Hypomagnesemia can be a problem for dialysis patients because foods rich in Mg are also generally rich in potassium, which need to be avoided. Recently, an effort has been made to keep Mg on the high-normal side in dialysis patients by using high-Mg dialysate. A preliminary study evaluating a cohort of these patients in Germany showed that patients in the high-Mg dialysate group had a significantly higher iMg and had a significantly lower all-cause and cardiovascular 3-year mortality (14.5% vs 0% after adjusting for age and comorbidities) (See Figure 2 in Schmaderer et al., 2017; https:\/\/www.ncbi.nlm.nih.gov\/ pmc\/articles\/PMC5622686\/ [29]). These studies, and similar ones [30], suggest that maintaining a Mg level on the high-normal to slightly elevated side is beneficial for overall health.<\/p>\n

Summary<\/h3>\n

\u2022 Magnesium is an important electrolyte which plays a key role in numerous physiologic activities.<\/p>\n

\u2022 Most of the body\u2019s magnesium resides in muscle and bone, with only about 1% in the extracellular space.<\/p>\n

\u2022 This 1% of extracellular magnesium is critically important for maintaining homeostasis in many critical systems including ion transport, inflammation, muscle function, cardiac function, cell signalling, neurologic function and coagulation.<\/p>\n

\u2022 The physiologically active form of magnesium is the ionized fraction, which can vary widely from person to person and generally represents 55\u201370% of the extracellular magnesium.<\/p>\n

\u2022 Most analysers measure total magnesium rather than ionized magnesium, but total magnesium does not accurately represent ionized magnesium in roughly one-third of individuals.<\/p>\n

\u2022 There is no accurate formula for converting total magnesium to ionized magnesium thus it is critically important to measure ionized magnesium to assess magnesium status, especially in critically ill patients, patients at the extremes of age, perioperative patients, and patients with kidney disease.<\/p>\n

\u2022 Both chronically high and low magnesium can increase all-cause mortality. Acutely low magnesium can cause sudden cardiac death and potentially result in a more severe inflammatory response to infection.<\/p>\n

\u2022 Chronically low magnesium seems to play a role in accelerating atherosclerosis.<\/p>\n

\u2022 Magnesium supplementation may help mitigate some of the negative effects of chronically low magnesium levels.<\/p>\n<\/div><\/section>
\n

The author<\/strong>
\nDennis Begos MD, Associate Medical Director
\nMedical and Scientific Affairs, Nova Biomedical, Waltham, MA, USA<\/p>\n

*Corresponding author E-mail: dbegos@novabio.com<\/a><\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n

References<\/strong>
\n1. Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev 2003; 24(2): 47\u201366.
\n2. de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev 2015; 95(1): 1\u201346.
\n3. Saha H, Harmoinen A, Nisula M, Pasternack A. Serum ionized versus total magnesium in patients with chronic renal disease. Nephron 1998;
\n80(2): 149\u2013152.
\n4. Johansson M, Whiss PA. Weak relationship between ionized and total magnesium in serum of patients requiring magnesium status.
\nBiol Trace Elem Res 2007; 115(1): 13\u201321.
\n5. Yeh DD, Chokengarmwong N, Chang Y, Yu L, Arsenault C, et al. Total and ionized magnesium testing in the surgical intensive care unit
\n– Opportunities for improved laboratory and pharmacy utilization. J Crit Care 2017; 42: 147\u2013151.
\n6. Huijgen HJ, Soesan M, Sanders R, Mairuhu WM, Kesecioglu J, Sanders GT. Magnesium levels in critically ill patients. What should we measure?
\nAm J Clin Pathol 2000; 114(5): 688\u2013695.
\n7. Zhan J, Wallace TC, Butts SJ, Cao S, Ansu V, et al. Circulating ionized magnesium as a measure of supplement bioavailability: results from a
\npilot study for randomized clinical trial. Nutrients 2020; 12(5): 1245.
\n8. Cunningham J, Rodr\u00edguez M, Messa P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J 2012;
\n5(Suppl 1): i39-i51.
\n9. Elliott JP, Morrison JC, Bofill JA. Risks and benefits of magnesium sulfate tocolysis in preterm labor (PTL). AIMS Public Health 2016; 3(2):
\n348\u2013356.
\n10. Kreepala C, Kitporntheranunt M, Sangwipasnapaporn W, Rungsrithananon W, Wattanavaekin K. Assessment of preeclampsia risk by use of
\nserum ionized magnesium-based equation. Ren Fail 2018; 40(1): 99\u2013106.
\n11. Escuela MP, Guerra M, A\u00f1\u00f3n JM, Mart\u00ednez-Vizca\u00edno V, Zapatero MD, et al. Total and ionized serum magnesium in critically ill patients.
\nIntensive Care Med 2005; 31(1): 151\u2013156.
\n12. Cheungpasitporn W, Thongprayoon C, Qian Q. Dysmagnesemia in hospitalized patients: prevalence and prognostic importance. Mayo Clin
\nProc 2015; 90(8): 1001\u20131010.
\n13. Ferr\u00e8 S, Li X, Adams-Huet B, Maalouf NM, Sakhaee K, et al. Association of serum magnesium with all-cause mortality in patients with and
\nwithout chronic kidney disease in the Dallas Heart Study. Nephrol Dial Transplant 2018; 33(8): 1389\u20131396.
\n14. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of
\ncardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr 2013; 98(1): 160\u2013173.
\n15. Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, et al. Results from the Atherosclerosis Risk in Communities study suggest that low
\nserum magnesium is associated with incident kidney disease. Kidney Int 2015; 87(4): 820\u2013827.
\n16. DiNicolantonio JJ, Liu J, O’Keefe JH. Magnesium for the prevention and treatment of cardiovascular disease. Open Heart 2018; 5(2):
\ne000775.
\n17. Soliman HM, Mercan D, Lobo SS, M\u00e9lot C, Vincent JL. Development of ionized hypomagnesemia is associated with higher mortality rates.
\nCrit Care Med 2003; 31(4): 1082\u20131087.
\n18. de Baaij JH, Hoenderop JG, Bindels RJ. Regulation of magnesium balance: lessons learned from human genetic disease. Clin Kidney J 2012;
\n5(Suppl 1): i15-i24.
\n19. Velissaris D, Karamouzos V, Pierrakos C, Aretha D, Karanikolas M. Hypomagnesemia in Critically Ill Sepsis Patients. J Clin Med Res 2015; 7(12):
\n911\u2013918.
\n20. Maier JA, Malpuech-Brug\u00e8re C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for
\natherosclerosis, inflammation and thrombosis. Biochim Biophys Acta 2004; 1689(1): 13\u201321.
\n21. Kircelli F, Peter ME, Sevinc Ok E, Celenk FG, Yilmaz M, et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a
\ndose-dependent manner. Nephrol Dial Transplant 2012; 27(2): 514\u2013521.
\n22. van de Wal-Visscher ER, Kooman JP, van der Sande FM. Magnesium in chronic kidney disease: should we care? Blood Purif 2018; 45(1\u20133):
\n173\u2013178.
\n23. Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, et al. Vascular smooth muscle cell differentiation to an osteogenic
\nphenotype involves TRPM7 modulation by magnesium. Hypertension 2010; 56(3): 453\u2013462.
\n24. Ravn HB, Kristensen SD, Vissinger H, Husted SE. Magnesium inhibits human platelets. Blood Coagul Fibrinolysis 1996; 7(2): 241\u2013244.
\n25. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012 Sep; 32(9): 2045\u20132051.
\n26. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular
\nmortality in patients undergoing hemodialysis. Kidney Int 2014; 85(1): 174\u2013181.
\n27. Hruby A, O’Donnell CJ, Jacques PF, Meigs JB, Hoffmann U, McKeown NM. Magnesium intake is inversely associated with coronary artery
\ncalcification: the Framingham Heart Study. JACC Cardiovasc Imaging 2014; 7(1): 59\u201369.
\n28. Lacson E Jr, Wang W, Ma L, Passlick-Deetjen J. Serum magnesium and mortality in hemodialysis patients in the United States: a cohort study.
\nAm J Kidney Dis 2015; 66(6): 1056\u20131066.
\n29. Schmaderer C, Braunisch MC, Suttmann Y, Lorenz G, Pham D, et al. Reduced mortality in maintenance haemodialysis patients on high versus
\nlow dialysate magnesium: a pilot study. Nutrients 2017; 9(9): 926.
\n30. Leenders NHJ, Vervloet MG. Magnesium: a magic bullet for cardiovascular disease in chronic kidney disease? Nutrients 2019; 11(2): 455.<\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n